Prof Kevin Pfleger

Professor Kevin Pfleger MA(Cambridge) PhD(Edinburgh) HonFBPhS is Director Biomedical and Health Innovation at The University of Western Australia (UWA) and the Western Australian Life Sciences Innovation Hub.

He is also Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research, Chief Scientific Advisor to Dimerix Limited and former President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists.

Professor Pfleger has developed globally-recognised expertise in molecular pharmacology over the last 25 years. He also has experience in research translation, being a named inventor on a number of patent families and being a spin-out company Chief Scientific Officer for over 6 years.

This company, Dimerix, is now listed on the Australian stock exchange and is in Phase 3 clinical trials for chronic kidney disease. Professor Pfleger is also a scientific co-founder of RAGE Biotech and an advisor/mentor to a number of other start-ups and entrepreneurs.

Professor Pfleger supports innovation and entrepreneurship training as Chair of Biodesign Australia and Perth Biodesign, and was also the Founding Co-Director of the Australian Clinical Entrepreneur Program.

He serves on the Western Australian (WA) Future Health Research and Innovation Fund Innovation Expert Committee, WA Health and Medical Life Sciences Industry Advisory Group, Sector Advisory Panel for the WA Health and Medical Research Strategy, national steering committees of the Bridge and BridgeTech programs and AusBiotech WA State Committee.

Keywords: Molecular pharmacology; Bioluminescence Resonance Energy Transfer; BRET; Inflammatory disease; Biodesign.